公开(公告)号：WO2011123947A8

公开(公告)日：2011-12-22

申请号：PCT/CA2011000387

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK ,  CUMMING GRAHAM ,  PATEL NARENDA KUMAR B ,  FORREST BRYAN T ,  LIU YONG ,  LI SZE-WAN ,  SAMPSON PETER BRENT ,  EDWARDS LOUISE G ,  PAULS HEINZ W

Inventor： CUMMING GRAHAM ,  PATEL NARENDA KUMAR B ,  FORREST BRYAN T ,  LIU YONG ,  LI SZE-WAN ,  SAMPSON PETER BRENT ,  EDWARDS LOUISE G ,  PAULS HEINZ W

IPC: C07D403/04 ,  C07D231/56 ,  C07D413/14

CPC classification number: C07D403/10 ,  A61K31/5377 ,  A61K45/06 ,  C07D231/56 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

Abstract: The present invention is directed to novel synthetic methods for preparing a spiro cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.

Abstract translation: 本发明涉及用于制备由结构式（A）表示的螺环丙基吲哚啉酮化合物的新型合成方法：（A）或其药学上可接受的盐。 还包括本文所述的合成中间体。

公开(公告)号：WO2011123946A8

公开(公告)日：2011-12-08

申请号：PCT/CA2011000386

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK ,  SAMPSON PETER BRENT ,  LIU YONG ,  LI SZE-WAN ,  FORREST BRYAN T ,  PAULS HEINZ W ,  EDWARDS LOUISE G ,  FEHER MIKLOS ,  PATEL NARENDRA KUMAR B ,  LAUFER RADOSLAW ,  PAN GUOHUA

Inventor： SAMPSON PETER BRENT ,  LIU YONG ,  LI SZE-WAN ,  FORREST BRYAN T ,  PAULS HEINZ W ,  EDWARDS LOUISE G ,  FEHER MIKLOS ,  PATEL NARENDRA KUMAR B ,  LAUFER RADOSLAW ,  PAN GUOHUA

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00 ,  C07D403/04

CPC classification number: C07D403/10 ,  A61K31/5377 ,  A61K45/06 ,  C07D231/56 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: (I). Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Abstract translation: 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：（I）。 由该结构式表示的化合物是激酶抑制剂，因此在此公开用于治疗癌症。 本文提供了结构式中变量的定义。

公开(公告)号：EP2556071A4

公开(公告)日：2013-09-04

申请号：EP11764988

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  LIU YONG ,  LI SZE-WAN ,  FORREST BRYAN T ,  PAULS HEINZ W ,  EDWARDS LOUISE G ,  FEHER MIKLOS ,  PATEL NARENDRA KUMAR B ,  LAUFER RADOSLAW ,  PAN GUOHUA

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14

CPC classification number: C07D403/10 ,  A61K31/5377 ,  A61K45/06 ,  C07D231/56 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

公开(公告)号：EP3068786A4

公开(公告)日：2017-04-12

申请号：EP14861448

申请日：2014-11-14

Applicant: UNIV HEALTH NETWORK

Inventor： LAUFER RADOSLAW ,  NG GRACE ,  LI SZE-WAN ,  PAULS HEINZ W ,  LIU YONG ,  PATEL NARENDRA KUMAR B

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract translation: 本教导提供由结构式（1-0）表示的化合物或其药学上可接受的盐。 还描述了药物组合物及其使用方法。

公开(公告)号：EP2556070A4

公开(公告)日：2013-10-23

申请号：EP11764989

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK

Inventor： CUMMING GRAHAM ,  PATEL NARENDA KUMAR B ,  FORREST BRYAN T ,  LIU YONG ,  LI SZE-WAN ,  SAMPSON PETER BRENT ,  EDWARDS LOUISE G ,  PAULS HEINZ W

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00 ,  C07D231/56 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14

CPC classification number: C07D403/10 ,  A61K31/5377 ,  A61K45/06 ,  C07D231/56 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

公开(公告)号：EP2920181A4

公开(公告)日：2016-07-27

申请号：EP13855919

申请日：2013-11-15

Applicant: UNIV HEALTH NETWORK

Inventor： LIU YONG ,  PAULS HEINZ W ,  LAUFER RADOSLAW ,  LI SZE-WAN ,  SAMPSON PETER BRENT ,  FEHER MIKLOS ,  NG GRACE ,  PATEL NARENDRA KUMAR B ,  LANG YUNHUI

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract translation: 本发明提供由结构式（1-0）表示的化合物或其药学上可接受的盐。 还描述了药物组合物及其使用方法。

公开(公告)号：EP2235004A4

公开(公告)日：2011-05-04

申请号：EP08865534

申请日：2008-12-19

Applicant: UNIV HEALTH NETWORK

Inventor： PAULS HEINZ W ,  FORREST BRYAN T ,  LAUFER RADOSLAW ,  FEHER MIKLOS ,  SAMPSON PETER BRENT ,  PAN GUOHUA ,  LIU YONG ,  LI SZE-WAN

IPC: C07D403/06 ,  A61K31/416 ,  A61K31/4192 ,  A61P35/00 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

CPC classification number: C07D403/06 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

公开(公告)号：EP3212652A4

公开(公告)日：2018-04-25

申请号：EP15855932

申请日：2015-10-09

Applicant: UNIV HEALTH NETWORK

Inventor： LAUFER RADOSLAW ,  NG GRACE ,  BROKX RICHARD ,  PAULS HEINZ W ,  LI SZE-WAN ,  MASON JACQUELINE M ,  BRAY MARK R

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06

CPC classification number: A61K31/519 ,  A61K45/06 ,  C07D487/04

Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

公开(公告)号：EP2766352A4

公开(公告)日：2015-06-03

申请号：EP12840107

申请日：2012-10-12

Applicant: UNIV HEALTH NETWORK UHN

Inventor： PAULS HEINZ W ,  LAUFER RADOSLAW ,  LIU YONG ,  LI SZE-WAN ,  FORREST BRYAN T ,  LANG YUNHUI ,  PATEL NARENDRA KUMAR B ,  EDWARDS LOUISE G ,  NG GRACE ,  SAMPSON PETER BRENT ,  FEHER MIKLOS ,  AWREY DONALD E

IPC: C07D409/12 ,  A61K31/416 ,  A61P35/00 ,  C07D231/56 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07D451/06 ,  C07D491/107 ,  C07D493/10

CPC classification number: C07D231/56 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07D451/06 ,  C07D491/107 ,  C07D493/10

Abstract: The present teachings provide a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

公开(公告)号：IL287394D0

公开(公告)日：2021-12-01

申请号：IL28739421

申请日：2021-10-19

Applicant: UNIV HEALTH NETWORK ,  LI SZE WAN ,  BRAY MARK ROBERT

Inventor： LI SZE-WAN ,  BRAY MARK ROBERT

IPC: A61K31/5377 ,  A61P35/00

Abstract: Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1:0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2° ± 0.2 in 2θ.